PriceTargets.com logo

Abcam - ABCM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.00
  • Forecasted Upside: -4.13%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$23.99 As of 12/12/2023 01:00 AM ET
+0 (0.00%)
Get New Abcam Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABCM

Analyst Price Target is $23.00
▼ -4.13% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Abcam in the last 3 months. The average price target is $23.00, with a high forecast of $23.00 and a low forecast of $23.00. The average price target represents a -4.13% upside from the last price of $23.99.

This chart shows the closing price for ABCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Abcam. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector PerformLow
8/29/2023SVB LeerinkDowngradeOutperform ➝ Market PerformLow
8/29/2023SVB SecuritiesDowngradeOutperform ➝ Market PerformLow
8/28/2023William BlairDowngradeOutperform ➝ Market PerformLow
8/22/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector PerformLow
6/20/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
6/16/2023Bank of AmericaUpgradeNeutral ➝ BuyLow
4/28/2023Royal Bank of CanadaBoost Target$21.50 ➝ $23.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
9/5/2022Panmure GordonUpgradeHold ➝ BuyLow
3/15/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00Medium
10/15/2021Peel HuntUpgradeHoldHigh
9/30/2021JPMorgan Chase & Co.Reiterated RatingNeutralMedium
6/24/2021Berenberg BankReiterated RatingHoldLow
3/12/2021Berenberg BankReiterated RatingHoldLow
3/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
3/9/2021Royal Bank of CanadaReiterated RatingOutperformLow
3/9/2021SVB LeerinkLower TargetOutperform$26.00 ➝ $25.00Low
1/28/2021Morgan StanleyInitiated CoverageHold$21.00Low
1/27/2021SVB LeerinkBoost TargetOutperform$22.00 ➝ $26.00Low
1/12/2021Royal Bank of CanadaUpgradeSector Perform ➝ OutperformHigh
11/16/2020William BlairInitiated CoverageOutperformLow
11/16/2020Bank of AmericaInitiated CoverageNeutral$20.00Low
11/16/2020SVB LeerinkInitiated CoverageOutperform$22.00Low
11/16/2020Morgan StanleyInitiated CoverageEqual Weight$21.00Low
11/9/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformMedium
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
9/23/2023
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Abcam logo
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $23.99
Low: $23.99
High: $23.99

50 Day Range

MA: $23.88
Low: $23.07
High: $23.99

52 Week Range

Now: $23.99
Low: $12.48
High: $25.32

Volume

3,300 shs

Average Volume

3,080,005 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Abcam?

The following Wall Street sell-side analysts have issued stock ratings on Abcam in the last year: Bank of America Co., Royal Bank of Canada, SVB Leerink LLC, SVB Securities, and William Blair.
View the latest analyst ratings for ABCM.

What is the current price target for Abcam?

1 Wall Street analysts have set twelve-month price targets for Abcam in the last year. Their average twelve-month price target is $23.00, suggesting a possible downside of 4.1%. Royal Bank of Canada has the highest price target set, predicting ABCM will reach $23.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $23.00 for Abcam in the next year.
View the latest price targets for ABCM.

What is the current consensus analyst rating for Abcam?

Abcam currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABCM, but not buy more shares or sell existing shares.
View the latest ratings for ABCM.

What other companies compete with Abcam?

Other companies that are similar to Abcam include RayzeBio, Crinetics Pharmaceuticals, ImmunoGen, Roivant Sciences and Option Care Health. Learn More about companies similar to Abcam.

How do I contact Abcam's investor relations team?

The company's listed phone number is 44-0-12-2369-6000 and its investor relations email address is [email protected]. The official website for Abcam is www.abcam.com. Learn More about contacing Abcam investor relations.